Scott T Reents Receives Stock Award at AbbVie Inc (ABBV) — SEC Form 4, Feb 20, 2026
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Equity Position
60.4K sh
11,577 → 60,415
Equity Change
+421.9%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Scott T Reents CIK 0001937048 |
CFO
|
Scott T Reents at AbbVie Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at AbbVie Inc
| 2026-03-03 | - | — | View |
| 2025-03-18 | Sell | -$3,746,526 | View |
| 2025-03-04 | - | — | View |
| 2025-02-18 | Award | — | View |
| 2024-03-01 | Sell | -$2,509,002 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 par valueF1 | 2026-02-18 | A - Award/Grant | 25,062 A | $0.00 | — | 36,639 | Direct |
| Common Stock, $0.01 par valueF2 | 2026-02-18 | A - Award/Grant | 8,910 A | $0.00 | — | 45,549 | Direct |
| Common Stock, $0.01 par valueF3 | 2026-02-18 | A - Award/Grant | 7,606 A | $0.00 | — | 53,155 | Direct |
| Common Stock, $0.01 par valueF4 | 2026-02-18 | A - Award/Grant | 7,260 A | $0.00 | — | 60,415 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Option (Right to buy)F5 | $230.04 | 2026-02-18 | A - Award/Grant | 21,937 A | $0.00 | 2036-02-17 | 21,937 Common Stock | Direct |
Footnotes (5)
- F1
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Show more
- F2
- Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Show more
- F3
- Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Show more
- F4
- Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Show more
- F5
- Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029. Show more
Related filings at AbbVie Inc
Institutional Holders
13F holders · Jun 30, 2026
4,249
institutional managers reporting a position
Largest by reported value
- Black Rock, Inc. $37.6B
- Vanguard Capital Management Llc $29B
- State Street Corporation $20.8B
5%+ Holders · 13D/G
1 filer
Other insiders at AbbVie Inc
GET /v1/forms/4/0001937048-26-000002
API docs
View Original SEC Filing